BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  RedHill Biopharma’s Crohn’s Drug Shows Promise for Disease Remission

  RedHill Biopharma, with offices in Tel Aviv, Israel and Raleigh, North Carolina, announced positive topline data from its first Phase III trial of RHB-104 for Crohn’s disease. It met all primary endpoint and key secondary endpoints.

  July 30, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Skeptical Investors Should Take Another Look at AbbVie

  Investors have been skeptical about AbbVie lately, particularly after last week’s second-quarter financial report. That doesn’t make all that much sense, given that the company reported net revenues of $8.278 billion for the quarter.

  July 30, 2018

   · 

  3 min read

   · 

  Mark Terry